Skip Header

 
Contribute Send feedback

Reviewed, UniProtKB/Swiss-Prot P52701 (MSH6_HUMAN)

Last modified November 25, 2008. Version 107. Feed History...

Clusters with 100%, 90%, 50% identity | Documents (7) | Third-party data | Customize display text xml rdf/xml gff fasta
Names and origin · Protein attributes · General annotation (Comments) · Ontologies · Binary interactions · Alternative products · Sequence annotation (Features) · Sequences · References · Web resources · Cross-references · Entry information · Relevant documents

Names and origin

Protein namesRecommended name:
    DNA mismatch repair protein Msh6
Alternative name(s):
    MutS-alpha 160 kDa subunit
    G/T mismatch-binding protein
      Short name=GTMBP
      Short name=GTBP
    p160
Gene names
Name: MSH6
Synonyms: GTBP
OrganismHomo sapiens (Human)
Taxonomic identifier9606 [NCBI]
Taxonomic lineageEukaryotaMetazoaChordataCraniataVertebrataEuteleostomiMammaliaEutheriaEuarchontogliresPrimatesHaplorrhiniCatarrhiniHominidaeHomo

Protein attributes

Sequence length1360 AA.
Sequence statusComplete.
Sequence processingThe displayed sequence is not processed.
Protein existenceEvidence at protein level.

General annotation (Comments)

Function

Component of the post-replicative DNA mismatch repair system (MMR). Heterodimerizes with MSH2 to form MutS alpha, which binds to DNA mismatches thereby initiating DNA repair. When bound, MutS alpha bends the DNA helix and shields approximately 20 base pairs, and recognizes single base mismatches and dinucleotide insertion-deletion loops (IDL) in the DNA. After mismatch binding, forms a ternary complex with the MutL alpha heterodimer, which is thought to be responsible for directing the downstream MMR events, including strand discrimination, excision, and resynthesis. ATP binding and hydrolysis play a pivotal role in mismatch repair functions. The ATPase activity associated with MutS alpha regulates binding similar to a molecular switch: mismatched DNA provokes ADP-->ATP exchange, resulting in a discernible conformational transition that converts MutS alpha into a sliding clamp capable of hydrolysis-independent diffusion along the DNA backbone. This transition is crucial for mismatch repair. MutS alpha may also play a role in DNA homologous recombination repair.

Subunit structure

Heterodimer consisting of MSH2-MSH6 (MutS alpha). Forms a ternary complex with MutL alpha (MLH1-PMS1). Interacts with EXO1. Part of the BRCA1-associated genome surveillance complex (BASC), which contains BRCA1, MSH2, MSH6, MLH1, ATM, BLM, PMS2 and the RAD50-MRE11-NBS1 protein complex. This association could be a dynamic process changing throughout the cell cycle and within subnuclear domains. Interacts with ATR.

Subcellular location

Nucleus.

Post-translational modification

The N-terminus is blocked.

Phosphorylated upon DNA damage, probably by ATM or ATR.

Phosphorylated by PRKCZ, which may prevent MutS alpha degradation by the ubiquitin-proteasome pathway.

Involvement in disease

Defects in MSH6 are the cause of hereditary non-polyposis colorectal cancer type 5 (HNPCC5) [MIM:600678]. Mutations in more than one gene locus can be involved alone or in combination in the production of the HNPCC phenotype (also called Lynch syndrome). Most families with clinically recognized HNPCC have mutations in either MLH1 or MSH2 genes. HNPCC is an autosomal, dominantly inherited disease associated with marked increase in cancer susceptibility. It is characterized by a familial predisposition to early onset colorectal carcinoma (CRC) and extra-colonic cancers of the gastrointestinal, urological and female reproductive tracts. HNPCC is reported to be the most common form of inherited colorectal cancer in the Western world. Cancers in HNPCC originate within benign neoplastic polyps termed adenomas. Clinically, HNPCC is often divided into two subgroups. Type I: hereditary predisposition to colorectal cancer, a young age of onset, and carcinoma observed in the proximal colon. Type II: patients have an increased risk for cancers in certain tissues such as the uterus, ovary, breast, stomach, small intestine, skin, and larynx in addition to the colon. Diagnosis of classical HNPCC is based on the Amsterdam criteria: 3 or more relatives affected by colorectal cancer, one a first degree relative of the other two; 2 or more generation affected; 1 or more colorectal cancers presenting before 50 years of age; exclusion of hereditary polyposis syndromes. MSH6 mutations appear to be associated with atypical HNPCC and in particular with development of endometrial carcinoma or atypical endometrial hyperplasia, the presumed precursor of endometrial cancer. Defects in MSH6 are also found in familial colorectal cancers (suspected or incomplete HNPCC) that do not fulfill the Amsterdam criteria for HNPCC.

Defects in MSH6 are a cause of susceptibility to endometrial cancer [MIM:608089].

Sequence similarities

Belongs to the DNA mismatch repair mutS family.

Contains 1 PWWP domain.

Ontologies

Keywords

   Biological processDNA damage
DNA repair
   Cellular componentNucleus
   Coding sequence diversityAlternative splicing
Polymorphism
   DiseaseDisease mutation
Hereditary nonpolyposis colorectal cancer
   LigandATP-binding
DNA-binding
Nucleotide-binding
   PTMPhosphoprotein
   Technical term3D-structure
Direct protein sequencing

Gene Ontology (GO)

   Biological processDNA damage response, signal transduction resulting in induction of apoptosis

Inferred from sequence or structural similarity. Source: UniProtKB

determination of adult life span

Inferred from sequence or structural similarity. Source: UniProtKB

isotype switching

Inferred from sequence or structural similarity. Source: UniProtKB

meiotic mismatch repair

Inferred from sequence or structural similarity. Source: UniProtKB

negative regulation of DNA recombination

Inferred from direct assay. Source: UniProtKB

positive regulation of helicase activity

Inferred from direct assay. Source: UniProtKB

response to UV

Inferred from sequence or structural similarity. Source: UniProtKB

somatic hypermutation of immunoglobulin genes

Inferred from sequence or structural similarity. Source: UniProtKB

   Cellular componentMutSalpha complex Ref.1

Inferred from direct assay. Source: HGNC

   Molecular functionATP binding

Inferred from electronic annotation. Source: InterPro

dinucleotide insertion or deletion binding

Inferred from mutant phenotype. Source: HGNC

protein binding Ref.1

Inferred from physical interaction. Source: UniProtKB

purine-specific mismatch base pair DNA N-glycosylase activity

Inferred from mutant phenotype. Source: HGNC

Complete GO annotation...

Binary interactions

Alternative products

This entry describes 2 isoforms produced by alternative splicing. [Align] [Select]
Isoform GTBP-N (identifier: P52701-1)

This isoform has been chosen as the 'canonical' sequence. All positional information in this entry refers to it. This is also the sequence that appears in the downloadable versions of the entry.
Isoform GTBP-alt (identifier: P52701-2)

The sequence of this isoform differs from the canonical sequence as follows:
     1058-1068: DVLLCLANYSR → GKTLNKLVLRL
     1069-1360: Missing.

Sequence annotation (Features)

Feature keyPosition(s)LengthDescriptionGraphical viewFeature identifier

Molecule processing

Chain1 – 13601360DNA mismatch repair protein Msh6
PRO_0000115207

Regions

Domain92 – 15463PWWP
Nucleotide binding1134 – 11418ATP Potential
Compositional bias34 – 374Poly-Ala
Compositional bias201 – 2099Poly-Glu
Compositional bias1118 – 11236Poly-Glu

Amino acid modifications

Modified residue141Phosphoserine
Modified residue411Phosphoserine
Modified residue431Phosphoserine
Modified residue791Phosphoserine
Modified residue911Phosphoserine
Modified residue1371Phosphoserine
Modified residue1391Phosphothreonine
Modified residue2001Phosphoserine
Modified residue2191Phosphoserine
Modified residue2271Phosphoserine
Modified residue2521Phosphoserine
Modified residue2541Phosphoserine
Modified residue2561Phosphoserine
Modified residue2611Phosphoserine
Modified residue3481Phosphoserine
Modified residue8301Phosphoserine
Modified residue9241Phosphothreonine

Natural variations

Alternative sequence1058 – 106811DVLLCLANYSR → GKTLNKLVLRL in isoform GTBP-alt.
VSP_003291
Alternative sequence1069 – 1360292Missing in isoform GTBP-alt.
VSP_003292
Natural variant131K → T: dbSNP rs41294988.
VAR_038032
Natural variant201A → V in colorectal/endometrial cancer.
VAR_043943
Natural variant251A → V: dbSNP rs35462442.
VAR_038033
Natural variant391G → E: dbSNP rs1042821.
VAR_004490
Natural variant541G → A in CRC; uncertain pathogenicity.
VAR_043944
Natural variant651S → L: dbSNP rs41294984.
VAR_038034
Natural variant991K → N in CRC; uncertain pathogenicity.
VAR_043945
Natural variant1281R → L No impairment of heterodimerization with MSH2 and of in vitro mismatch repair capacity.
VAR_043946
Natural variant1441S → I in suspected HNPCC5 and CRC. dbSNP rs3211299.
VAR_012955
Natural variant2201E → D: dbSNP rs1800938.
VAR_012956
Natural variant2211E → D: dbSNP rs41557217 and dbSNP rs61748079.
VAR_042274
Natural variant2851S → I in CRC.
VAR_012957
Natural variant2951K → R in multiple colorectal adenoma.
VAR_043947
Natural variant3401F → S in CRC, breast cancer and leukemia.
VAR_043948
Natural variant3961L → V Rare polymorphism. dbSNP rs2020908.
VAR_012958
Natural variant4491L → P in colorectal/endometrial cancer; uncertain pathogenicity.
VAR_043949
Natural variant4681R → H: dbSNP rs41295268.
VAR_038035
Natural variant4921M → V in HNPCC5.
VAR_042275
Natural variant5031S → C
VAR_038036
Natural variant5091V → A
VAR_043950
Natural variant5221Q → R in CRC; uncertain pathogenicity.
VAR_043951
Natural variant5381Y → S: dbSNP rs728619.
VAR_038037
Natural variant5661G → R in CRC; partial functional loss.
VAR_012959
Natural variant5801S → L: dbSNP rs41295270.
VAR_038038
Natural variant6191E → D in CRC; uncertain pathogenicity.
VAR_043952
Natural variant6231P → A: dbSNP rs3136334.
VAR_029244
Natural variant6231P → L No impairment of heterodimerization with MSH2 and of in vitro mismatch repair capacity.
VAR_043953
Natural variant6851G → A in CRC.
VAR_043954
Natural variant6981Q → E in suspected HNPCC; could be a polymorphism.
VAR_012960
Natural variant7251I → M in CRC; uncertain pathogenicity.
VAR_043955
Natural variant7281K → T No impairment of heterodimerization with MSH2 and of in vitro mismatch repair capacity. dbSNP rs35552856.
VAR_043956
Natural variant7721R → Q in CRC.
VAR_043957
Natural variant7721R → W in HNPCC5.
VAR_043958
Natural variant7871A → V in CRC; uncertain pathogenicity.
VAR_043959
Natural variant8001V → A in CRC; somatic mutation.
VAR_043960
Natural variant8001V → L May be a rare polymorphism.
VAR_012961
Natural variant8031D → G in CRC.
VAR_012962
Natural variant8501Y → C in suspected HNPCC5 and CRC.
VAR_012963
Natural variant8541K → M in CRC; could be a polymorphism. dbSNP rs34374438.
VAR_043961
Natural variant8781V → A in suspected HNPCC5, colorectal/endometrial cancer and CRC. dbSNP rs2020912.
VAR_012964
Natural variant8861I → V: dbSNP rs2020914.
VAR_014902
Natural variant9011R → H in colorectal/endometrial cancer.
VAR_043962
Natural variant9761R → H in CRC; sporadic.
VAR_012965
Natural variant10211A → D in CRC; uncertain pathogenicity.
VAR_043963
Natural variant10311D → V in CRC; somatic mutation.
VAR_043964
Natural variant10761R → C in CRC; uncertain pathogenicity.
VAR_043965
Natural variant10871P → T in CRC.
VAR_012966
Natural variant10951R → H in CRC; uncertain pathogenicity.
VAR_043966
Natural variant11001T → M in CRC; uncertain pathogenicity.
VAR_043967
Natural variant11581C → R in CRC; somatic mutation.
VAR_043968
Natural variant11631E → V in HNPCC5.
VAR_043969
Natural variant11931E → K in endometrial cancer; display marked impairment of heterodimerization with MSH2 and of in vitro mismatch repair capacity.
VAR_043970
Natural variant12131D → V
VAR_004491
Natural variant12191T → I in CRC; uncertain pathogenicity.
VAR_043971
Natural variant12321V → L: dbSNP rs41295276.
VAR_038039
Natural variant12341E → Q: dbSNP rs35717727.
VAR_038040
Natural variant12481H → D in CRC; uncertain pathogenicity.
VAR_043972
Natural variant12601V → I
VAR_004492